

University Investment in Drug Discovery

ALTHOUGH YOUR SPECIAL SECTION ON DRUG Discovery (29 July, pp. 721–735) highlighted important contributions from academia, it did not recognize an increasingly relevant but underappreciated and underutilized role for academic research in drug discovery.

Universities invest many millions in basic research that exposes disease mechanisms and therefore unearths new targets. Yet few have invested in the relatively modest infrastructure required to put their discoveries to the test. As a result, many promising targets gather dust on the university shelf. This need not be the case. Developing appropriate assays, screening modest-sized compound libraries, using medical chemistry to further develop leads, and conducting preliminary tests in animal models

“Universities invest many millions in basic research that exposes disease mechanisms... [y]et few have invested in the relatively modest infrastructure required to put their discoveries to the test.”

—IVINSON

are functions well suited to academia. Academic researchers often have the best understanding of individual targets, routinely design and refine in vitro assays, and have ready access to and experience with the most appropriate animal models.

The pharmaceutical industry (and, to a lesser extent, biotech) look at drug discovery ideas emanating from academic research as too risky and early in development to warrant significant investment. This risk aversion is in large part a reflection of the economic climate and the changing winds of drug-discovery received wisdom. To bring these ideas to a stage where pharma will look at them more carefully, we can and should advance them through at least the first stages of drug discovery. Demonstrating a credible mechanism and target, proprietary lead compounds, and preliminary in vivo efficacy will be enough to bring some of our industry colleagues back to the table. But this will only happen when academics stop treating drug discovery as the intellectually inferior domain of the commer-

cial sector and start seeing it as the natural development of their research.

ADRIAN J. IVINSON

Director, Harvard Center for Neurodegeneration and Repair, Harvard Medical School, Boston, MA 02115, USA. E-mail: adrian_ivinson@hms.harvard.edu

A Place at the Pharma Table for Women?

THE ARTICLE “IT’S STILL A MAN’S WORLD AT THE top of big pharma research” (J. Mervis, Special Section on Drug Discovery, News, 29 July, p. 724) resonated with me. As a scientist in Merck R&D in the 1990s, it was clear to me that women did not have a place at the decision-making table. As years of diversity committees, on-site day care, mentoring programs, coaching, and other HR efforts rolled by, many talented women figured out that their only career path at Merck R&D was out the door.

Merck, and I suspect many other “big pharma” companies, are feeling the effects of having some of their best talent leaving and taking their brainpower elsewhere. We have started companies, taken senior positions in biotechnology firms, and become leaders in government and academia. Perhaps this brain drain of talented women has exacerbated the problem of the empty product pipelines of big pharma.

The men in charge of R&D tend to promote and recruit other men with whom they feel the most comfortable and ignore talented women. Until they are forced by progressive senior executives to include, in significant numbers, women in their club, they will not change.

LINDA RHODES

Rhodes & Associates, LLC, 3 White Birch Lane, Holmdel, NJ 07733, USA. E-mail: lrhodes@alcherabio.com

Costs and Benefits of Regulating Mercury

MERCURY IS KNOWN TO HAVE DETRIMENTAL effects on human health (1), so it is surprising to read that it may not be worthwhile to regulate mercury releases from U.S. power plants (“Regulating mercury: what’s at stake?”, T. Gayer, R. W. Hahn, Letters, 8 July, p. 244). Although there is legitimate debate about the cost of implementation

and the choice of emission reduction approach, we feel that the estimated benefits of emission reduction of \$100 million accrued over 15 years have been grossly understated by Gayer and Hahn.

Their proposed benefit was based on a study of willingness-to-pay for chelation therapy to reduce lead in children. However, lowering levels of lead by chelation has not been demonstrated to improve cognition (2). Similarly, although chelation therapy may remove methyl- and ethylmercury, it cannot reverse central nervous system damage (3), implying that prenatal mercury exposure leads to lifelong lost benefits, irrespective of money spent on removing the causal agent from the body after the damage has been done.

Thus, an approach based on lifelong losses in income better estimates the benefits of reducing mercury emissions (4). This approach attributes subsequent losses in lifelong earnings as a result of lower IQ to the loss in a child’s IQ from prenatal methylmercury exposure. The estimated lifelong losses in income for all U.S. children affected in the year 2000 was \$1.3 billion per year (range: \$0.1 to \$6.5 billion), which would lead to a \$15.9-billion loss in income (range: \$1.2 to \$79.9 billion, discounted at a rate of 3% per annum) over the 15-year period considered by Gayer and Hahn. Therefore, by only considering the loss of earnings due to exposure to mercury generated by U.S. power plants, lowering prenatal exposure by reducing emissions may have considerable economic benefits, likely exceeding the estimated costs of \$4 billion to \$19 billion.

DIRK ZELLER AND SHAWN BOOTH

Fisheries Centre, University of British Columbia, Vancouver, BC V6T 1Z4, Canada. E-mail: d.zeller@fisheries.ubc.ca

References

1. P. Grandjean *et al.*, *Neurotoxicol. Teratol.* **19**, 417 (1997).
2. K. N. Dietrich *et al.*, *Pediatrics* **114**, 19 (2004).
3. X. Liu *et al.*, *Pediatrics* **110**, 787 (2002).
4. L. Trasande, P. J. Landrigan, C. Schechter, *Environ. Health Perspect.* **113**, 590 (2005).

Response

IN OUR STUDY, WE ESTIMATED THE COSTS and benefits of the U.S. Environmental Protection Agency’s (EPA) power plant mercury regulation. To estimate the benefits of mercury reduction, we considered each link in the pathway, including the reduction of emissions from U.S. power plants; reductions in mercury deposition; reductions of methylmercury in U.S. freshwater and marine fish; reductions of methylmercury consumption from U.S. fish by U.S. resi-

dents; reductions of methylmercury in U.S. women of childbearing age; and IQ improvements in U.S. children. For each link, we used the best available evidence and, if anything, tended to err on the side of overstating benefits. Only at the end did we monetize estimates of IQ improvements, based on a study of parental willingness to pay for IQ increases through chelation.

Zeller and Booth contend that our estimate of the benefits of mercury reduction is “grossly understated” based on their claim that our estimate of the value of an IQ point is flawed. They cite a study by Trasande *et al.* (1) claiming that benefits of mercury reduction are \$1.3 billion per year. Unfortunately, they are comparing apples with oranges. The \$1.3 billion estimate (1) is for the benefits of eliminating all U.S. power plant mercury emissions. Zeller and Booth apply this annual measure of complete elimination of power plant mercury emissions to each year from 2005 to 2020. It is incorrect to compare the costs of EPA’s regulation that eliminates a fraction of the power plant emissions to the benefits of eliminating all power plant emissions of mercury (which would cost considerably more to achieve).

Zeller and Booth suggest that the monetized benefits we use for IQ may be under-

stated. We agree that the willingness-to-pay numbers for IQ may understate the benefits of IQ. The value of an IQ point suggested by Trasande *et al.* (1) is about an order of magnitude greater than our estimate. However, as we noted in our Letter, using their estimate does not change our finding that the costs of the regulation are likely to exceed benefits.

Zeller and Booth’s claim of mercury’s detrimental effects might be overstated. They cite Grandjean *et al.*’s study (2) of the Faroe Islands to support their claim that the detrimental effects of mercury are “known.” They do not mention a study of the Seychelles (3) that did not find evidence of such a link and a study in New Zealand (4) that found mixed evidence. Even Grandjean *et al.* (2) found mixed results for the relationship between mercury and IQ scores. Nonetheless, we used conservative estimates of the IQ-mercury relationship even when they are not statistically different from zero.

We think that policy-makers should design regulations for controlling mercury emissions so that expected benefits exceed expected costs. The current approach fails that test.

TED GAYER¹ AND ROBERT W. HAHN²

¹Public Policy Institute, Georgetown University,

3520 Prospect Street, NW, Washington, DC 20007, USA. ²American Enterprise Institute–Brookings Joint Center, 1150 17th Street, NW, Washington, DC 20036, USA.

References

1. L. Trasande, P. J. Landrigan, C. Schechter, *Environ. Health Perspect.* **113**, 590 (2005).
2. P. Grandjean *et al.*, *Neurotoxicol. Teratol.* **19**, 417 (1997).
3. G. J. Myers *et al.*, *Lancet* **361**, 1686 (2003).
4. T. Kjellstrom *et al.*, *Physical and Mental Development of Children with Prenatal Exposure to Mercury from Fish. Stage 2: Interviews and Psychological Tests at Age 6* (National Swedish Environmental Board, Solna, Sweden, 1989).

Landscape Corridors: Possible Dangers?

THE REPORT “EFFECTS OF LANDSCAPE CORRIDORS on seed dispersal by birds” (1 July, p. 146) by D. J. Levey *et al.* shows that landscape corridors increase the movement of birds between patches of habitat in a fragmented landscape, and that this facilitates the movement of bird-dispersed seeds. Another study, in the same experimental setting, found that corridors increase inter-patch insect pollination (1). Both studies conclude by emphasizing the conservation value of habitat corridors. However, landscape corridors also facilitate the spread of

invasive alien species (2). Although the potential negative effects of habitat connectivity were stated almost two decades ago (3), these seem to have been largely ignored in the evaluation of corridors as a conservation tool.

Alien plants with attractive flowers and fruit can hijack generalist pollinators and seed dispersers from indigenous plant species (4). By increasing alien propagule pressure, invasive species outcompete and replace local biota (5). Indeed, the spread of invaders is often facilitated by corridors, either natural (rivers, coastlines, ridges) or man-made (roads and railways). In this context, it is worth mentioning that all the plants considered in the South Carolina studies [Levey *et al.*; (1)] are aliens of concern in parts of the world [*Lantana camara* (6), *Rudbeckia hirta* (7), *Morella* (= *Myrica cerifera*) (8)]. Moreover, the Eastern Bluebird (*Sialia sialis*) that dispersed *Morella* seeds is also known to disperse seeds of the alien tree *Sapium sebiferum* in the eastern United States (9).

Presently, land managers are advised to build habitat corridors to reduce the effects of habitat fragmentation, but habitat barriers are also built to manage the spread of invasive species (10). It is ironic that habitat corridors do not always link the seemingly separate fields of conservation and invasion biology. Both habitat fragmentation and invasive species have resulted in the loss of large sections of biodiversity, and their combined impacts must be better understood. The modeling tools developed in the present study present a useful opportunity for developing a more integrated approach to the evaluation of corridors as a conservation management tool.

ȘERBAN PROCHEȘ, JOHN R. U. WILSON,
RUAN VELDTMAN, JESSE M. KALWIJ,

DAVID M. RICHARDSON, STEVEN L. CHOWN

Centre for Invasion Biology, Department of Zoology and Botany and Department of Conservation Ecology, University of Stellenbosch, Matieland 7602, South Africa.

References

1. P. A. Townsend, D. J. Levey, *Ecology* **86**, 466 (2005).
2. D. A. Saunders, R. J. Hobbs, Eds., *Nature Conservation 2: The Role of Corridors* (Surrey Beatty & Sons, Chipping Norton, Australia, 1991).
3. D. Simberloff, *Annu. Rev. Ecol. Syst.* **19**, 473 (1988).
4. D. M. Richardson, N. Allsopp, C. M. D'Antonio, S. J. Milton, M. Rejmánek, *Biol. Rev.* **75**, 65 (2000).
5. J. L. Lockwood, P. Cassey, T. Blackburn, *Trends Ecol. Evol.* **20**, 223 (2005).
6. See www.gisp.org.
7. J. S. Meidell, H. L. Oppenheimer, R. T. Bartlett, *Bishop Mus. Occ. Pap.* **49**, 17 (1997).
8. E. U. Zajac, *Monogr. Bot.* **40**, 1 (1974).
9. I. J. Renne, W. C. Barrow, L. A. J. Randall, W. C. Bridges, *Div. Distrib.* **8**, 285 (2002).
10. K. A. With, *Conserv. Biol.* **16**, 1192 (2002).

Response

PROCHEȘ ET AL. POINT OUT THAT CORRIDORS may increase the spread of exotic species. We agree that the function of corridors is blind to the geographic origin of species that use them.

ADVERTISER DIRECTORY

» advances in:

Neuroscience

The Challenge of Neurological Disease A variety of new tools and techniques promise to take neuroscientists closer to their goal of understanding the molecular basis of neurological diseases such as Alzheimer's and Parkinson's. BY PETER SCHENK AND JERRY ROBERTS



Neurodegenerative diseases pose some of medicine's most difficult challenges. Not only do they have complex genetic and environmental components, but they also affect the brain, making diagnosis difficult. Advances in neuroscience and genetics have begun to shed light on the molecular basis of these diseases. The challenge now is to translate this knowledge into effective treatments. This special section of *Advances in Neuroscience* features a variety of articles that explore the latest research in this field. The path to cure is often a long one, but recent advances have given researchers a head start by exploring such fields as genetics and proteomics, and by using animal models to study human disease. The special section includes articles on the latest research in Alzheimer's disease, Parkinson's disease, and Huntington's disease. It also features a review of the latest research on the role of the gut in neurodegeneration. The special section is a must-read for anyone interested in the latest research in neuroscience.

Two Promising Diseases Huntington's disease is a rare, inherited brain disorder that causes progressive mental and physical decline. It is caused by a mutation in the huntingtin gene. The special section includes an article by Peter Schenk and Jerry Roberts, who discuss the latest research on the role of the gut in Huntington's disease. They argue that the gut may play a role in the development and progression of the disease, and that targeting the gut may be a promising new approach to treatment.

Alzheimer's Disease Alzheimer's disease is the most common form of dementia, and it is caused by a complex interplay of genetic and environmental factors. The special section includes an article by Peter Schenk and Jerry Roberts, who discuss the latest research on the role of the gut in Alzheimer's disease. They argue that the gut may play a role in the development and progression of the disease, and that targeting the gut may be a promising new approach to treatment.

Neurodegenerative Diseases Neurodegenerative diseases are a group of conditions that cause the progressive loss of neurons in the brain. This special section of *Advances in Neuroscience* features a variety of articles that explore the latest research in this field. The path to cure is often a long one, but recent advances have given researchers a head start by exploring such fields as genetics and proteomics, and by using animal models to study human disease. The special section includes articles on the latest research in Alzheimer's disease, Parkinson's disease, and Huntington's disease. It also features a review of the latest research on the role of the gut in neurodegeneration. The special section is a must-read for anyone interested in the latest research in neuroscience.

Neuroscience Neuroscience is the study of the brain and nervous system. It is a rapidly growing field, and it is expected to continue to grow in the future. This special section of *Advances in Neuroscience* features a variety of articles that explore the latest research in this field. The path to cure is often a long one, but recent advances have given researchers a head start by exploring such fields as genetics and proteomics, and by using animal models to study human disease. The special section includes articles on the latest research in Alzheimer's disease, Parkinson's disease, and Huntington's disease. It also features a review of the latest research on the role of the gut in neurodegeneration. The special section is a must-read for anyone interested in the latest research in neuroscience.

The following organizations have placed ads in the Special Advertising Section

Advances in:

Neuroscience

The Challenge of Neurological Disease

| ADVERTISER | Page |
|------------------|------|
| Carl Zeiss | 877 |
| Nikon | 874 |

Turn to page 875



The issue before conservation biologists and land managers, however, is not whether corridors are without costs, but whether they provide a net benefit in the maintenance of natural communities. In this context, it is important to keep in mind that the benefits of habitat corridors to native species have been clearly demonstrated, whereas their impact on the spread of exotic species is largely conjectural.

Rather than debating the potential drawbacks of corridors, scientists should focus

attention on understanding how corridors function and which types of species are most likely to benefit from them. For example, because invasive species are excellent dispersers (by definition), corridors may not further increase their successful colonization of new habitat patches. On the other hand, many native species of conservation concern have limited dispersal abilities and therefore would be more likely to benefit from corridors.

TECHNICAL COMMENT ABSTRACTS

COMMENT ON "A Brief History of Seed Size"

Peter J. Grubb, David A. Coomes, Daniel J. Metcalfe

Moles *et al.* (Reports, 28 Jan. 2005, p. 576) suggested that larger plants have larger seeds because larger offspring offset the lower survivorship to adulthood inherent in longer juvenile periods. However, that view is not consistent with the wedge-shaped relationship between log seed size and log plant height. Most importantly, the range of feasible seed sizes increases dramatically with whole-plant size.

Full text at www.sciencemag.org/cgi/content/full/310/5749/783a

RESPONSE TO COMMENT ON "A Brief History of Seed Size"

Angela T. Moles, David D. Ackerly, Campbell O. Webb, John C. Tweddle, John B. Dickie, Mark Westoby

Mechanical constraints might prevent small plants from making very large seeds. However, data for 2589 species reveal an absence of large plants that make very small seeds. This cannot be explained by mechanical constraint. Coordination of life history traits provides a more plausible explanation for the overall shape of the relationship between seed mass and plant size.

Full text at www.sciencemag.org/cgi/content/full/310/5749/783b

Understanding corridors at a mechanistic level will better enable us to extrapolate their effects from well-studied species and small spatial scales to less-known species and landscape scales; our paper aimed toward this goal.

DOUGLAS J. LEVEY,¹ BENJAMIN M. BOLKER,¹
JOSHUA J. TEWKSBURY,^{1*} SARAH SARGENT,²
NICK M. HADDAD³

¹Department of Zoology, University of Florida, Post Office Box 118525, Gainesville, FL 32611-8525, USA. ²Department of Biology, Allegheny College, Meadville, PA 16335, USA. ³Department of Zoology, North Carolina State University, Raleigh, NC 27695-7617, USA.

*Current Address: Department of Biology, Box 351800, University of Washington, Seattle, WA 98195-1800, USA.

Letters to the Editor

Letters (~300 words) discuss material published in *Science* in the previous 6 months or issues of general interest. They can be submitted through the Web (www.submit2science.org) or by regular mail (1200 New York Ave., NW, Washington, DC 20005, USA). Letters are not acknowledged upon receipt, nor are authors generally consulted before publication. Whether published in full or in part, letters are subject to editing for clarity and space.

Costs and Benefits of Regulating Mercury

Dirk Zeller and Shawn Booth

Science **310** (5749), 777-779.
DOI: 10.1126/science.310.5749.777d

| | |
|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ARTICLE TOOLS | http://science.sciencemag.org/content/310/5749/777.4 |
| REFERENCES | This article cites 7 articles, 2 of which you can access for free http://science.sciencemag.org/content/310/5749/777.4#BIBL |
| PERMISSIONS | http://www.sciencemag.org/help/reprints-and-permissions |

Use of this article is subject to the [Terms of Service](#)

Science (print ISSN 0036-8075; online ISSN 1095-9203) is published by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. 2017 © The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. The title *Science* is a registered trademark of AAAS.